Galectin Therapeutics Inc.

GALT Healthcare Biotechnology

In the quarter to June 2026, EPS fell 16.7%, free cash flow grew 63.1% and total debt fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.62 0.09 −2.43%
Market cap
$374.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

0.09 2.42 2.15 0.10
Net Debt/EBITDA
(18.63) (34.90) (29.91) (22.97)
Debt/Assets
697.66% 684.70% 861.16% 705.92%
Debt/Equity
(0.73) (1.06) (1.04) (0.76)
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.43 1.09 0.76 0.27
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
(2.31) (1.74) (2.05) (1.99)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.06) (0.09) (0.06) (0.04)
Cash per Share
0.18 0.28 0.21 0.20
Shareholders Equity per Share
(1.92) (1.97) (1.98) (2.08)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(1.92) (1.97) (1.98) (2.08)
Free Cash Flow
(3.54) (6.04) (3.87) (2.44)
Working Capital
(123.72) 11.41 8.38 (136.96)
Net Current Asset Value
(123.72) (126.29) (130.30) (137.02)
Other line items
Quick Ratio
0.08 2.21 1.93 0.09
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.06) (0.09) (0.06) (0.04)
Capex per Share
0.00 0.00 0.00 0.00
Average Payables
4.09 4.45 4.83 4.80
Average Assets
20.92 18.51 12.64 15.21
Average Common Equity
(110.25) (116.85) (123.46) (129.22)

Fold the line items

Columns are period end dates